Just as first Lu­cen­tis biosim­i­lar wins ap­proval, Roche snags an OK for an eas­i­er route of ad­min­is­tra­tion

It’s been a month since the FDA cleared the first biosim­i­lar to Roche’s block­buster wet age-re­lat­ed mac­u­lar de­gen­er­a­tion (AMD) drug ranibizum­ab. But the phar­ma gi­ant …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER